Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

Zeidner JF, et al.

Citation

J Clin Oncol. 2025 Aug 10;43(23):2606-2615.

PMID

40504618